Atrial Fibrillation
Friday, June 21st, 2013
Circulation: April 11, 2013 Background—Left atrial (LA) ganglionated plexi (GP) are part of the intrinsic cardiac autonomic nervous system and implicated in the pathogenesis of atrial fibrillation. High frequency stimulation is used to identify GP sites in humans. The effect of ablation on neural pathways connecting GPs in humans is unknown. Methods and Results—Thirty patients undergoing […]
Atrial Fibrillation
Friday, June 21st, 2013
Circulation: April 3, 2013, Background—Pulmonary vein isolation (PVI) for atrial fibrillation is associated with a transient increased risk of thromboembolic and hemorrhagic events. We hypothesized that dabigatran can be safely used as an alternative to continuous warfarin for the periprocedural anticoagulation in PVI. Methods and Results—A total of 999 consecutive patients undergoing PVI were included; 376 […]
Clinical Trials
Friday, June 21st, 2013
Ann Intern Medicine: June 18, 2013 Background: In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), a large randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation. Objective: To determine the […]
Clinical Trials
Friday, June 21st, 2013
STROKEAHA. June 18, 2013, Background and Purpose—Previous clinical studies suggested benefit for poststroke recovery when MLC601 was administered between 2 weeks and 6 months of stroke onset. The Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study tested the hypothesis that MLC601 is superior to placebo in acute, moderately severe ischemic stroke within a 72-hour […]
Clinical Trials
Friday, June 21st, 2013
NMQF: June 18, 2013 The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that it is partnering with the National Minority Quality Forum (NMQF) and Microsoft to help increase diversity in clinical trials. “Promoting awareness and creating connectivity that can translate into enhanced participation in clinical trials by a diverse patient population is a priority […]
Clinical Trials
Friday, June 21st, 2013
BMC Medical Research Methodology: June 18, 2013 Background The inclusion of randomized controlled trials (RCTs) reported in conference abstracts in systematic reviews is controversial, partly because study design information and risk of bias is often not fully reported in the abstract. The Association for Research in Vision and Ophthalmology (ARVO) requires trial registration of abstracts […]
Clinical Trials
Friday, June 21st, 2013
Trials: June 19, 2013 Background One mechanism to increase participation in research is to solicit potential research participants’ general willingness to be recruited into clinical trials. Such research permissions and consents typically are collected on paper upon patient registration. We describe a novel method of capturing this information electronically. Purpose The objective is to enable the collection of […]
Atrial Fibrillation
Friday, June 21st, 2013
JACC: June 1, 2013 Objective The primary objective was to compare the net clinical benefit of dabigatran 110mg bid and 150mg bid with that of warfarin in patients with atrial fibrillation (AF). Background In patients with AF, dabigatran 110mg bid and 150mg bid are associated with similar rates of death. However, the higher dose reduces ischemic stroke […]
Therapies
Friday, June 21st, 2013
JAMA: June 19, 2013 Importance Randomized clinical trials suggest the benefit of intravenous tissue-type plasminogen activator (tPA) in acute ischemic stroke is time dependent. However, modest sample sizes have limited characterization of the extent to which onset to treatment (OTT) time influences outcome; and the generalizability of findings to clinical practice is uncertain. Objective To […]
Therapies
Friday, June 21st, 2013
STROKEAHA: June 18, 2013 Background and Purpose—Previous economic studies outside Australia have demonstrated that patients treated with tissue-type plasminogen activator (tPA) within 4.5 hours of stroke onset have lower healthcare costs than those not. We aim to perform cost-effectiveness analysis of intravenous tPA in an Australian setting. Methods—Data on clinical outcomes and costs were derived for […]
